Q3 2024 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Madrigal Pharmaceuticals Inc (MDGL) reported strong net sales of $62 million for the third quarter, driven by high demand for Rezdiffra.
- The company achieved its goal of securing coverage for 80% of commercial lives a full quarter ahead of schedule.
- Rezdiffra is recognized as a foundational therapy for NASH, with healthcare providers showing high confidence in its efficacy and tolerability.
- The company completed enrollment in the MAESTRO-NASH OUTCOMES trial, positioning Rezdiffra as a potential first therapy for patients with compensated NASH cirrhosis.
- Madrigal Pharmaceuticals Inc (MDGL) has a strong cash position of $1 billion, supporting ongoing and future launches, including a planned launch in Europe in 2025.
- SG&A expenses increased significantly to $107.6 million from $27.6 million in the previous year, primarily due to the expansion of commercial operations.
- Gross to net adjustments are expected to be choppy, particularly in early quarters, with potential impacts from insurance reops and the IRA in Q1 2025.
- There is uncertainty regarding the impact of potential competition from GLP-1 class drugs, such as semaglutide, on Rezdiffra's market position.
- The company is still in the early stages of the Rezdiffra launch, with only 2% of the target 315,000 NASH patients currently on treatment.
- Persistence and refill rates for Rezdiffra are still being evaluated, with more data needed to fully understand long-term patient adherence.
Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals Third Quarter 2024 Earnings Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I'd like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.
Thank you, Marvin. Good morning, everyone, and thank you for joining us to discuss Madrigal's third quarter 2024 earnings. We issued a press release this morning and have a slide deck that accompanies this webcast, which we'll post on the Investor Relations section of our website right after the call. On the call with me today is Bill Sibold, Chief Executive Officer; and Mardi Dier, Chief Financial Officer. They will provide prepared remarks, and then we'll take your questions.
Our goal is to keep today's call to about 45 minutes. Please note, on slide 2, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the risks that may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
